Drugs / DS-1001b
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03030066 | Jan 2017 → Jan 2021 overdue | glioma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04458272 | Jul 2020 → Mar 2023 overdue | grade II glioma | Daiichi Sankyo | Active not recruiting | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-1001b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03030066 ↗ |
| Action | Inhibit | “selective inhibitor of mutant IDH1” PMID 41206766 ↗ Mar 2026 |
| Route | Oral | “Oral administration” NCT03030066 ↗ |
| Target | IDH1 | “mutant IDH1 selective inhibitor” PMID 35722822 ↗ Feb 2023 |